Meeting
2020 ASCO Virtual Scientific Program
Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors.
Authors
Zhenguang Wang
Molecular & Immunological Department, Bio-therapeutic Department, Chinese PLA General Hospital, Beijing, China
Zhenguang Wang , Meixia Chen , Yan Zhang , Yang Liu , Qingming Yang , Jing Nie , Lianjun Shen , Pengfei Jiang , Jiaping He , Xun Ye , Wei Cao , Haoyi Wang , Weidong Han
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT03747965
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3038)
DOI
10.1200/JCO.2020.38.15_suppl.3038
Abstract #
3038
Poster Bd #
102
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
First Author: Tanya B. Dorff
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer.
First Author: Jiuwei Cui
Poster
2024 ASCO Annual Meeting
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
First Author: Boyu Hu